Hyperscalers may benefit as chip stocks struggle, according to Morgan Stanley strategists. The once-hot semiconductor trade has seen a cooling in the last couple of weeks, which is not only likely to ...

Ligand Pharma (LGND) stock jumped in the final week of June, but the proximate cause was the pricing of $625M of convertible ...

XBI, which includes both SLS and IBRX, is on track for its strongest monthly performance since December 2023.

A Delaware judge dismissed a former Aurion Biotech executive's challenge to a stockholder's alleged takeover of the company, ...

Venture funding and steady openings are pushing Peninsula biotech to hire — and some displaced tech workers may land in labs.

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...

Amidst regulatory turmoil and a funding resurgence, companies provide insights on how they are navigating the changing ...

Vedana Therapeutics emerged from stealth with a $46M Series A. Led by local biotech veterans, the Seattle startup is developing next-gen, at-home migraine injections.

Antares Therapeutics, a Scorpion spinout with labs in South San Francisco and Boston, has inked a collaboration with Swiss ...

Business combination transaction with Voyager Acquisition Corp. complete, creating a Nasdaq-listed, innovative biopharmaceutical company focused on next-generation cancer therapies of novel bispecific ...

NDV-01 Phase 2 NMIBC results, Phase 3 mid-2026 outlook, competition, and $160m financing—read the full analysis.

While the US and China command the race to the top, up-and-coming players like Spain could offer the UK some pointers as it ...